Sirna Therapeutics is opposing an Australian RNAi-related patent obtained by rival Alnylam Pharmaceuticals through its July 2003 acquisition of German RNAi shop Ribopharma, marking at least the second time Sirna has challenged this international intellectual property portfolio.

Alnylam reported the opposition in a filing with the US Securities and Exchange Commission published last week. The filing also provided additional details regarding the company's amended IP deal with the Max Planck Society.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.